



MEMORIAL SLOAN KETTERING CANCER CENTER (MSKCC) ZUCKERMAN RESEARCH CENTER NEW YORK, NEW YORK

Chairs: Julie George | Trudy Oliver | Taofeek Owonikoko | J.T. Poirier

WEDNESDAY, APRIL 3, 2019

Time	Event
16:00 - 18:30	Registration: Zuckerman Research Center Lobby
18:30 - 18:40	Welcome and Introduction: Giorgio V. Scagliotti, IASLC President
18:40 - 18:45	Survivor Address: Montessa Lee Title: Breaking the Stigma and Forget-Me-Nots
18:45 - 19:25	Keynote Address: Anton Berns Title: Lessons from the Mouse SCLC Model
19:25 - 20:00	Session 1: Pathology Chairs: Elisabeth Brambilla, Bill Travis
19:25 - 19:40	Dedication to Adi Gazdar: Ignacio Wistuba
19:40 - 20:00	Diagnosis of SCLC - Historical Evolution: Bill Travis
20:00 - 21:30	Reception/Dinner
21:30	Shuttle: MSKCC to Roosevelt Hotel

THURSDAY, APRIL 4, 2019

Time	Event	Presenter
07:00	Shuttle: Roosevelt Hotel to MSKCC	
07:30	Breakfast: Zuckerman Research Center Lobby	
07:30 - 17:00	Registration: Zuckerman Research Center Lobby	
08:00 - 09:40	Session 2: Omics Chair: Julie George	
08:00 - 08:20	News from the Small Cell Lung Cancer Genome	Julie George
08:20 - 08:40	Transformation of Adenocarcinoma to SCLC	Young Seok Ju
08:40 - 09:00	WNT Pathway Alterations in Recurrent SCLC	Ramaswamy Govindan
09:00 - 09:20	Utility of SCLC Circulating Tumor Cells and CDX Panel	Caroline Dive
09:20 - 09:40	MYC Drives a Metabolically Distinct Subtype of SCLC	Trudy Oliver
09:40 - 10:15	Poster Session & Networking Break	

THURSDAY, APRIL 4, 2019

Time	Event	Presenter
10:15 – 11:35	Session 3: Cell of Origin, Development and Tumor Initiation Chair: Kate Sutherland	
10:15 – 10:35	Neuroendocrine Stem Cells: Cells that Initiate SCLC	Mark Krasnow
10:35 – 10:55	SCLC-Subtype Specific Epigenome and Developmental Transcription Factor Networks	Jane Johnson
10:55 – 11:15	POU2F3 in Tuft Cell-Like Variant of SCLC	Chris Vakoc
11:15 – 11:35	Destabilizers and Trajectories of SCLC Subtypes	Vito Quaranta
11:35 – 13:00	Lunch: Zuckerman Research Center Lobby	
13:00 – 14:40	Session 4: Tumor Heterogeneity and Tumor Progression Chair: Julien Sage	
13:00 – 13:20	Determinants of Progression in Precancerous Cells	Kwon Park
13:20 – 13:40	MYC Family Activity in Precancerous Cells	Martin Sos
13:40 – 14:00	RB1 Deficiency and Aurora B Kinase Dependence	Mathew Oser
14:00 – 14:20	CyTOF Analysis of SCLC Under Treatment	Jonathan Lehman
14:20 – 14:40	Molecular and Cellular Mechanisms of SCLC Metastasis	Julien Sage
14:40 – 15:00	Poster Session & Networking Break	
15:00 – 16:40	Session 5: Platforms for Discovery Chair: Anton Berns	
15:00 – 15:20	Identifying New Therapeutic Vulnerabilities for SCLC	John Minna
15:20 – 15:40	Modeling the Origins of SCLC from Human Embryonic Stem Cells	Joyce Chen
15:40 – 16:00	MAST1 and Platinum Sensitivity	Sumin Kang
16:00 – 16:20	GEMMs as Discovery Platforms for Therapy	David McFadden
16:20 – 16:40	CREBBP-deleted SCLC	David MacPherson
16:40 – 17:20	Poster Session & Networking Break	
17:20 – 19:00	Session 6: Targeted Therapies Chair: Giorgio Scagliotti	
17:20 – 17:40	DDR Inhibitors for SCLC	Lauren Byers
17:40 – 18:00	PARPi as Radiosensitizers in SCLC	Ben Lok
18:00 – 18:20	A DLL3-targeted Theranostic	J.T. Poirier
18:20 – 18:40	Polo-like Kinase 1 (PLK1)	Taofeek Owonikoko
18:40 – 19:00	Targeting Cell Cycle, Genomic Instability and Transcriptional Vulnerabilities in SCLC	Camilla Christensen
19:00	Shuttle: MSKCC to Roosevelt Hotel	

FRIDAY, APRIL 5, 2019

Time	Event	Presenter
07:00	Shuttle: Roosevelt Hotel to MSKCC	
07:30	Breakfast: Zuckerman Research Center Lobby	
07:30 – 10:00	Registration: Zuckerman Research Center Lobby	
08:00 – 09:20	Session 7: Biomarkers Chair: Anna Farago	
08:00 – 08:20	Clinical Trial of Olaparib/Temozolomide	Anna Farago
08:20 – 08:40	Precision Medicine with DNA-Targeted Agents	Yves Pommier
08:40 – 09:00	Blood-based Studies in SCLC	Christine Lovly
09:00 – 09:20	SCLC Diagnosis Project	James Lee
09:20 – 09:40	Poster Session & Networking Break	
09:40 – 11:20	Session 8: Immunotherapy for SCLC Chair: Matt Hellmann	
09:40 – 10:00	Predictive Biomarkers for IO in SCLC	Matt Hellmann
10:00 – 10:20	Concurrent Versus Sequential IO in the Frontline	Leora Horn
10:20 – 10:40	SCLC Genomics and Combination Strategies	Se-Hoon Lee
10:40 – 11:00	NK Cells, HDAC6 and BET in SCLC	Hua Zhang
11:00 – 11:20	Harnessing the Innate Immune Response to Treat SCLC	Kate Sutherland
11:20 – 11:40	Poster Session & Networking Break	
11:40 – 12:10	Session 9: Recent and Ongoing Clinical Trials Chair: Taofeek Owonikoko	
11:40 – 11:45	Rova-T	David Carbone
11:45 – 11:50	PARP Inhibitors and Combinations	Charles Rudin
11:50 – 11:55	BCL-2 Inhibitors and Bromodomain Inhibitors	Christine Hann
11:55 – 12:00	Anti-fucosyl-GM1	Neal Ready
12:00 – 12:05	Lurbinectedin	Anna Farago
12:05 – 12:10	DLL3 BiTE® AMG 757s	Taofeek Owonikoko
12:10 – 12:30	Concluding Remarks Meeting Chairs: Julie George, Trudy Oliver, Taofeek Owonikoko, J.T. Poirier	